COMMUNIQUÉS West-GlobeNewswire

Revolo to Present at the 2026 AAAAI Annual Meeting
04/02/2026
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present a poster on its lead candidate, IRL201104 (‘1104), at the [...]
Pharmazz Presents Positive Phase IV Interim Analysis of Sovateltide for Acute Ischemic Stroke at the International Stroke Conference 2026
04/02/2026
WILLOWBROOK, Ill., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Pharmazz, Inc. today announced the presentation of positive interim results from its ongoing Phase IV clinical study of sovateltide (Tycamzzi®) in patients with acute [...]
‘Think Mortgage Calculator, But for Lung Cancer Risk’: A More User-Friendly Self-Serve Tool Gives Canadians and Healthcare Providers a Clearer Starting Point
04/02/2026
A simple online tool offered by Lung Health Foundation helps people understand their potential lung cancer risk – no medical knowledge, paperwork or special access required TORONTO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- [...]
Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies
04/02/2026
SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development , describing the application of [...]
Cozeva Earns 2026 Best in KLAS for Risk Adjustment: POC and In-Home Health Assessments
04/02/2026
SAN RAMON, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Cozeva, a healthcare technology company delivering a single, unified platform for value-based care, has earned the 2026 Best in KLAS distinction for Risk Adjustment: [...]
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Catheter Precision Announces Accelerated Momentum for LockeT Device with New Hospital Approvals and Strong Q1 Adoption Outlook
04/02/2026
FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a surge in hospital [...]
Normunity to Participate in the TD Cowen 46ᵗʰ Annual Health Care Conference
04/02/2026
BOSTON and NEW HAVEN, Conn., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Normunity , a clinical stage biotechnology company pioneering precision biologics, today announced that management will participate in the TD Cowen 46 th [...]
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
04/02/2026
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” [...]
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]
R1 Awarded ‘Best in KLAS’ Across Multiple RCM Categories for 2026
04/02/2026
Providers Recognize R1 for Unwavering Commitment to Launching Innovative Technology CHICAGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, has been named a [...]
Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois
04/02/2026
Award-winning spirits brand announce new distribution partner to oversee statewide distribution BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and [...]
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
04/02/2026
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose regimen of [...]
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
04/02/2026
T he Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, [...]
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share
04/02/2026
MONTREAL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
04/02/2026
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra [...]
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
04/02/2026
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Cannara annonce un placement privé stratégique sans intermédiaire de 6,3 millions $ CA au prix de 2,10 $ CA par action ordinaire
04/02/2026
MONTRÉAL, 04 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]

Pages